2018 American Transplant Congress
Post-Transplant Outcomes under the New HCC Exception Policy
Surgery, Johns Hopkins Medical Institute, Baltimore, MD.
In October 2015, OPTN implemented a new policy for liver allocation, under which hepatocellular carcinoma (HCC) patients receive exception points only after a 6-month delay.…2018 American Transplant Congress
Locoregional Treatments before Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study from the European Liver Transplant Registry
PurposeLocoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has shown to improve survival. However, effect of treatment types…2018 American Transplant Congress
Financial Burden of Liver Transplant vs Resection for HCC
Surgery, Indiana University, Indianapolis, IN.
There is considerable commentary regarding liver transplant vs resection for the treatment of hepatocellular carcinoma (HCC). While liver transplant provides longer survival when compared to…2018 American Transplant Congress
A Long-Term Experience with Expansion of Milan Criteria for Liver Transplant Recipients
1Duke University, Durham, NC; 2Baylor College of Medicine, Houston, TX.
Background: The Milan Criteria (MC) have historically determined eligibility for transplantation for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) Region 4 expanded…2018 American Transplant Congress
Intention to Treat Outcomes of Patients with Hepatocellular Carcinoma Downstaged to within Milan
Objectives: The success of LRT has served as a tool to select a subgroup of patients exceeding transplant criteria but potentially achieving meaningful outcome with…2018 American Transplant Congress
Validation of the alpha-Fetoprotein Model for Hepatocellular Carcinoma Recurrence after Transplantation in an Asian Population
Department of Surgery, Samsung Medical Center, Seoul, Republic of Korea.
Background: This study was designed to validate the alpha-fetoprotein model for predicting recurrence after LT in Korean HCC patients.Methods: Patients who underwent liver transplantation for…2018 American Transplant Congress
Cost Analysis of Loco-Regional Bridging Therapy for Hepatocellular Carcinoma: A National Study
Liver transplantation (LT) is cost-effective in the primary treatment of Hepatocellular carcinoma (HCC). Loco-regional therapies (LRTs) have increased as both primary therapy for HCC as…2018 American Transplant Congress
ABO‐incompatible Deceased Donor Liver Transplantation
ABO-incompatible liver transplantation (ILT) has increased over the past decade despite reports suggesting that adult ILT recipient have worse outcomes than ABO-compatible liver transplant (CLT)…2017 American Transplant Congress
Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma within Milan Criteria.
Introduction: The systemic inflammation biomarker, neutrophil-to-lymphocyte ratio (NLR) has been reported to be a predioctor of poor survival in patients with various cancers. The purpose…2017 American Transplant Congress
Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect.
Introduction: Liver transplantation (LT) is increasing treatment option for hepatocellular carcinoma (HCC) in East Asia. Over-immunosuppression is risk factor for oncologic outcome after transplantation and…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 23
- Next Page »